Results 181 to 190 of about 1,643,885 (289)

Stranger Rape or Impromptu Consensual Sex? Investigating Mock Juror Decision‐Making in a Genuine Contested Rape Trial

open access: yesBehavioral Sciences &the Law, EarlyView.
ABSTRACT The aim of this study was to better understand juror decision‐making in a less typical rape trial scenario where even prior acquaintance is disputed. Adopting an improved mock trial paradigm including a video‐recorded recreation of a genuine rape allegation and jury‐group deliberation, 156 jury‐eligible participants took part in 1 of 13 ...
Dominic Willmott, Rosie Woodhams
wiley   +1 more source

Adolescent Cyberviolence in South Korea: A Multi‐Year, National Population‐Based Study of Cyberviolence Prevalence (2017–2024)

open access: yesBehavioral Sciences &the Law, EarlyView.
ABSTRACT With the rise of digital technology, adolescent cyberviolence has become a growing global concern in public health and criminal justice. This study used nationally representative data from South Korea (2017–2024) to examine the prevalence of eight types of cyberviolence (i.e., verbal abuse, defamation, stalking, sexual abuse, personal ...
Heng Choon (Oliver) Chan   +2 more
wiley   +1 more source

Unveiling Bias: The Impact of Male Rape Myths and Stereotypes on Juror Verdicts in Male‐on‐Male Rape Trials

open access: yesBehavioral Sciences &the Law, EarlyView.
ABSTRACT This study examined how male rape myths, racial/ethnicity biases, and sexuality stereotypes influence verdicts in male‐on‐male rape trials—an area that is currently under‐researched. A sample of 463 participants read a mock rape trial, where both the defendant and complainant were male, with defendant ethnicity (White, Black, Asian) and ...
Lee J. Curley   +3 more
wiley   +1 more source

Artificial intelligence and machine learning‐assisted digital applications for biopharmaceutical manufacturing

open access: yesBiotechnology Progress, EarlyView.
Abstract Artificial intelligence and automation are no longer just buzzwords in the biopharmaceutical industry. The manufacturing of a class of biologics, comprising monoclonal antibodies, cell therapies, and gene therapies, is far more complex than that of traditional small molecule drugs.
Shyam Panjwani, Hao Wei, John Mason
wiley   +1 more source

Home - About - Disclaimer - Privacy